COO or MMSI: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both The Cooper Companies (COO) and Merit Medical (MMSI). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Dec 10, 2025

CNMD vs. MMSI: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Conmed (CNMD) or Merit Medical (MMSI). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Nov 24, 2025

Merit Medical (MMSI) Upgraded to Buy: What Does It Mean for the Stock?

Merit Medical (MMSI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Nov 21, 2025

Carillon Eagle Small Cap Growth Fund Q3 2025 Portfolio Update

Small-cap stocks extended their momentum into the third quarter. We believe Rambus' evolution from a licensing and patent company into a full-fledged product company is progressing well. Shake Shack stock pulled back following quarterly results that did not meet elevated expectations.

Seeking Alpha • Nov 13, 2025

CNMD or MMSI: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Conmed (CNMD) or Merit Medical (MMSI). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Nov 7, 2025

Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial

SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-randomized AVG cohort of the WAVE trial. Results of the AVG cohort were presented during the Late-Breaking Clinical Trials session at the annual VIVA Foundation3 Venous Endovascular Interventional Strategies (VEINS) conference held in Las Vegas, NV.

GlobeNewsWire • Nov 3, 2025

Merit Medical Q3 Earnings & Revenues Beat Estimate, Margins Expand

MMSI beats third-quarter 2025 estimates on strong revenue and margin growth, prompting a raised full-year outlook across segments.

Zacks Investment Research • Oct 31, 2025

Merit Medical Systems, Inc. (MMSI) Q3 2025 Earnings Call Transcript

Merit Medical Systems, Inc. ( MMSI ) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Martha Aronson - President, CEO & Director Brian Lloyd - Chief Legal Officer & Corporate Secretary Raul Parra - CFO & Treasurer Conference Call Participants Jason Bednar - Piper Sandler & Co., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Michael Matson - Needham & Company, LLC, Research Division John Young - Canaccord Genuity Corp., Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Michael Petusky - Barrington Research Associates, Inc., Research Division James Sidoti - Sidoti & Company, LLC Presentation Operator Thank you for standing by, and welcome to the Merit Medical Systems Third Quarter 2025 Earnings Conference Call.

Seeking Alpha • Oct 31, 2025

Merit Medical (MMSI) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Oct 31, 2025

Merit Medical (MMSI) Q3 Earnings and Revenues Surpass Estimates

Merit Medical (MMSI) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.86 per share a year ago.

Zacks Investment Research • Oct 30, 2025